<DOC>
	<DOCNO>NCT02717091</DOCNO>
	<brief_summary>The aim study clarify efficacy safety neoadjuvant FOLFIRINOX nab-paclitaxel + gemcitabine borderline resectable pancreatic cancer .</brief_summary>
	<brief_title>Neoadjuvant FOLFIRINOX Nab-paclitaxel With Gemcitabine Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Borderline resectable pancreatic cancer ( base NCCN guideline version 2.2015 ) 2. first treatment pancreatic cancer 3. performance status 0 1 4. adequate one marrow function 5. adequate renal function 6. obtain informed consent 1. active concomitant malignancy 2. severe medical condition ; contraindication FOLFIRINOX , paclitaxel gemcitabine 3. pregnant woman 4. informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>